Impact of M13 Bacteriophage and Administration Routes on Inflammation and Liver Injury in a Mouse Model of Sepsis
Abstract
Sepsis is a life-threatening condition characterized by a dysregulated immune response leading to organ failure. This study examines the immunomodulatory effects of the M13 bacteriophage in a cecal ligation and puncture (CLP) mouse model of sepsis, comparing intravenous and intraperitoneal delivery routes. Key outcomes included cytokine responses, bacterial burden, organ injury, and survival.
Sepsis was induced using the CLP model. M13 phages were verified by transmission electron microscopy and administered via IV or IP injection. Blood samples were collected at 24 hours, 72 hours, and day 5 for white blood cell, cytokine, and liver enzyme analysis. Bacterial burden was assessed by colony counts, liver injury by hematoxylin and eosin histology, and survival was monitored for 14 days.
CLP induction caused marked increases in WBC counts, cytokines, C-reactive protein (CRP), bacterial load, and liver damage. Following phage treatment, inflammatory markers, bacterial burden, and tissue injury declined substantially. IV administration more effectively reduced systemic inflammation, whereas IP administration provided stronger protection of liver and kidney function and resulted in higher survival rates.
M13 phage therapy demonstrates promising immunomodulatory and organ-protective effects in septic mice. The superior organ protection and survival benefits observed with IP delivery suggest potential translational value for targeted phage administration in sepsis management. Future studies should explore dose optimization, combination therapy, and mechanistic pathways to support clinical development.
2. Khosrojerdi A, Soudi S, Hosseini AZ, Khaligh SG, Hashemi SM. The combination of mesenchymal stem cell-and hepatocyte-derived exosomes, along with imipenem, ameliorates inflammatory responses and liver damage in a sepsis mouse model. Life Sci. 2023;326:121813.
3. Chiu C, Legrand M. Epidemiology of sepsis and septic shock. Curr Opin Anesthesiol. 2021;34(2):71-6.
4. Vincent J-L. Current sepsis therapeutics. EBioMedicine. 2022;86.
5. Srzić I, Adam VN, Pejak DT. Sepsis definition: What’s new in the treatment guidelines. Acta clinica croatica. 2022;61(Suppl 1):67.
6. Xu H-M, Xu W-M, Zhang L. Current status of phage therapy against infectious diseases and potential application beyond infectious diseases. Int J Cin Practice. 2022;2022(1):4913146.
7. Aswani VH, Shukla SK. An early history of phage therapy in the United States: is it time to reconsider? Clin Med Res. 2021;19(2):82-9.
8. Chevallereau A, Pons BJ, van Houte S, Westra ER. Interactions between bacterial and phage communities in natural environments. Nat Rev Microbiol. 2022;20(1):49-62.
9. Souza EBd, Pinto AR, Fongaro G. Bacteriophages as potential clinical immune modulators. Microorganisms. 2023;11(9):2222.
10. Safari Z, Sadeghizadeh M, Asgaritarghi G, Bardania H, Sadeghizadeh D, Soudi S. M13 phage coated surface elicits an anti-inflammatory response in BALB/c and C57BL/6 peritoneal macrophages. Int Immunopharmacol. 2022;107:108654.
11. Rahimi A, Soudi S, Vakilian S, Jamshidi-Adegani F, Sadeghizadeh M, Al-Hashmi S. Bacteriophage M13 modulates the sepsis-related inflammatory responses and organ damage in a CLP model. Shock. 2023;59(3):493-504.
12. Qadir MI, Mobeen T, Masood A. Phage therapy: Progress in pharmacokinetics. Brazilian J Pharmaceutical Sci. 2018;54:e17093.
13. Penziner S, Schooley RT, Pride DT. Animal models of phage therapy. Front Microbiol. 2021;12:631794.
14. Khosrojerdi A, Soudi S, Hosseini AZ, Khaligh SG, Hashemi SM. Imipenem alters systemic and liver inflammatory responses in CLP-induced sepsis mice in a dose-dependent manner. Int Immunopharmacol. 2021;93:107421.
15. Shahi E, Khosrojerdi A, Soudi S, Hosseini AZ. Mesenchymal stem cell-conditioned medium prevents inflammation-induced liver and lung damage in septic mice. Int Immunopharmacol. 2024;137:112407.
16. Khosrojerdi A, Soudi S, Hosseini AZ, Eshghi F, Shafiee A, Hashemi SM. Immunomodulatory and therapeutic effects of mesenchymal stem cells on organ dysfunction in sepsis. Shock. 2021;55(4):423-40.
17. van der Poll T, Shankar-Hari M, Wiersinga WJ. The immunology of sepsis. Immunity. 2021;54(11):2450-64.
18. Wang A, Xiao Z, Zhou L, Zhang J, Li X, He Q. The protective effect of atractylenolide I on systemic inflammation in the mouse model of sepsis created by cecal ligation and puncture. Pharm Biol. 2016;54(1):146-50.
19. Abaidullah M, Peng S, Kamran M, Song X, Sher AA, Chen Y, et al. Phageome-based vaccination and human innate immune modulation could be a useful strategy to control human Coronavirus infections. J Biol Regul Homeost Agents. 2021;35(3):865-80.
20. Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Górski A. A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med. 2009;9(4):303-12.
21. Górski A, Kniotek M, Perkowska-Ptasińska A, Mróz A, Przerwa A, Gorczyca W, et al. Bacteriophages and transplantation tolerance. Transplant Proc. 2006;38(1):331-3.
22. Kurzępa A, Dąbrowska K, Skaradziński G, Górski A. Bacteriophage interactions with phagocytes and their potential significance in experimental therapy. Clin Exp Med. 2009;9(2):93-100.
23. Secor PR, Michaels LA, Smigiel KS, Rohani MG, Jennings LK, Hisert KB, et al. Filamentous Bacteriophage Produced by Pseudomonas aeruginosa Alters the Inflammatory Response and Promotes Noninvasive Infection In Vivo. Infect Immun. 2017;85(1).
24. Miernikiewicz P, Kłopot A, Soluch R, Szkuta P, Kęska W, Hodyra-Stefaniak K, et al. T4 phage tail adhesin gp12 counteracts LPS-induced inflammation in vivo. Fronti Microbiol. 2016;7:1112.
25. Wilkinson JD, Pollack MM, Glass NL, Kanter RK, Katz RW, Steinhart CM. Mortality associated with multiple organ system failure and sepsis in pediatric intensive care unit. J Pediatr. 1987;111(3):324-8.
26. Hu H, Shi D, Hu C, Yuan X, Zhang J, Sun H. Dexmedetomidine mitigates CLP-stimulated acute lung injury via restraining the RAGE pathway. Am J Transl Res. 2017;9(12):5245.
27. Yehya N, Xin Y, Oquendo Y, Cereda M, Rizi RR, Margulies SS. Cecal ligation and puncture accelerates development of ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2015;308(5):L443-L51.
28. Senousy SR, Ahmed A-SF, Abdelhafeez DA, Khalifa MMA, Abourehab MA, El-Daly M. Alpha-chymotrypsin protects against acute lung, kidney, and liver injuries and increases survival in CLP-induced sepsis in rats through inhibition of TLR4/NF-κB pathway. Drug Des Devel Ther. 2022:3023-39.
29. Zhang H, Wang W, Fang H, Yang Y, Li X, He J, et al. GSK‐3β inhibition attenuates CLP‐induced liver injury by reducing inflammation and hepatic cell apoptosis. Med Inflamm. 2014;2014(1):629507.
30. Hung C-H, Kuo C-F, Wang C-H, Wu C-M, Tsao N. Experimental Phage Therapy in Treating Klebsiella pneumoniae-Mediated Liver Abscesses and Bacteremia in Mice. Antimicrob Agents Chemother. 2011;55(4):1358-65.
31. Ryan EM, Gorman SP, Donnelly RF, Gilmore BF. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol. 2011;63(10):1253-64.
| Files | ||
| Issue | Articles in Press | |
| Section | Original Article(s) | |
| Keywords | ||
| Bacteriophage Inflammation Liver Sepsis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
